CJC-1295

Chemical Makeup:

• Molecular Formula: C152, H252, N44, O42
• Molecular Weight: 3367.9 g/mol
• Synonyms: Tetrasubstituted GRF (1-29), Modified GRF 1-29, Drug Affinity Complex:GRF (referring to DAC variants).

Sequence:

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

CJC-1295 and Somatotropic Signaling

Research in murine and canine models suggests that CJC-1295 administration results in a sustained elevation of plasma Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1) levels. Unlike exogenous rhGH administration, which creates a constant "square wave" elevation, GHRH analogues appear to amplify the natural pulsatile secretory bursts. Studies indicate that the total area under the curve (AUC) for GH secretion is significantly increased following administration, suggesting an enhanced somatotropic profile without the complete suppression of endogenous production.

CJC-1295 and Lipolysis

In interactions with adipose tissue, GHRH analogues have been observed to influence lipid metabolism. Laboratory observations suggest that elevated GH levels, mediated by CJC-1295, may increase the expression of beta-adrenergic receptors on adipocytes. This upregulation is theorized to enhance lipolysis (the breakdown of triglycerides into free fatty acids and glycerol). Animal models subjected to GHRH treatment have demonstrated reductions in visceral adipose tissue mass, suggesting a shift in metabolic substrate utilization toward fatty acid oxidation.

CJC-1295 and Protein Synthesis

Investigations into skeletal muscle physiology suggest that the IGF-1 release stimulated by CJC-1295 plays a critical role in cellular repair and hypertrophy. IGF-1 is known to activate the PI3K/Akt/mTOR pathway, a primary regulator of protein synthesis. In models of muscle wasting or injury, subjects treated with GHRH analogues showed improved nitrogen retention and an accelerated rate of myofibrillar protein synthesis, indicating potential applications in offsetting catabolic states.

CJC-1295 and Sleep Architecture

It has been established in neuroendocrinology that GHRH acts as a sleep-promoting substance. Studies monitoring EEG patterns in subjects administered GHRH analogues indicate a modulation of sleep architecture, specifically an increase in the duration and intensity of Slow-Wave Sleep (SWS), or deep sleep. As the majority of endogenous growth hormone is secreted during SWS, this suggests a synergistic relationship where the peptide may both enhance sleep quality and optimize the nocturnal window for hormonal release.

If you're not 100% satisfied within the first 30 days, just send it back to us and we'll give you a full refund.

No need to worry about the return shipping - we've got you covered!

We offer fast and reliable shipping on all orders. You can expect to receive it within 7-12 business days based on your location.

Please contact our customer service team for assistance if you have any questions or concerns about your shipment.

Adverse Events in Research: 

In animal studies, adverse effects associated with the administration of GHRH analogues have been noted. These include transient vasodilation (flushing) at the time of administration, injection site reactions (irritation, erythema), and potential water retention. Prolonged elevation of GH and IGF-1 in test subjects has theoretically been linked to reduced insulin sensitivity; however, GHRH analogues generally impact blood glucose less drastically than exogenous HGH.

Research Use Only: 

This product is intended strictly for laboratory research and development purposes. It is not approved by the FDA or any other regulatory body for human consumption, diagnostic, or therapeutic use. It is not intended to diagnose, treat, cure, or prevent any disease. All purchases must be made by qualified researchers or licensed professionals.